-
Press Release
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
-
Press Release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
-
Press Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
-
Press Release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
-
Press Release
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
-
Press Release
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
-
Press Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
-
Press Release
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
-
Press Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
-
Press Release
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
-
Press Release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
-
Press Release
Novartis and US government reach agreement on lowering drug prices in the US